Applied Therapeutics Investor Relations Material

Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing innovative drugs for conditions with significant unmet medical needs. The company focuses on novel drug candidates targeting validated molecular pathways in diseases such as Galactosemia, Diabetic Cardiomyopathy, Diabetic Peripheral Neuropathy, and other areas with high unmet medical needs. Among its pipeline, notable drug candidates include AT-001, an aldose reductase inhibitor for diabetic complications; AT-007 for rare diseases such as SORD Deficiency; and AT-003, designed for diabetic retinopathy. Additionally, Applied Therapeutics is exploring AT-104, a PI3K inhibitor for orphan hematological oncology, specifically T Cell Acute Lymphoblastic Leukaemia. Applied Therapeutics is headquartered in New York, NY, and its shares are listed on the NASDAQ.